Protagenic Therapeutics, Inc. - Common Stock (PTIX)
4.2600
+1.9800 (86.84%)
NASDAQ · Last Trade: Aug 21st, 11:16 PM EDT
Detailed Quote
Previous Close
2.280
Open
3.640
Bid
4.000
Ask
4.020
Day's Range
3.550 - 6.200
52 Week Range
2.250 - 15.54
Volume
158,868,081
Market Cap
2.51M
PE Ratio (TTM)
-1.311
EPS (TTM)
-3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
7,000,599
Chart
About Protagenic Therapeutics, Inc. - Common Stock (PTIX)
Protagenic Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for neurological and psychiatric disorders. The company leverages its proprietary technologies to identify and develop peptides that target specific neuronal pathways, with the aim of addressing unmet medical needs in conditions such as depression and anxiety. Through its research and development efforts, Protagenic Therapeutics seeks to create effective treatment options that can enhance the quality of life for patients suffering from these complex disorders. Read More
Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BALA CYNWYD, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
